INVESTIGATION ALERT: Schall Law Firm Encourages Investors in Humanigen, Inc. with $100,000 Losses to Contact Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national firm specializing in shareholder rights litigation, announces that it is investigating claims on behalf of investors of Humanigen, Inc. (“Humanigen” or “the Company”) ) (NASDAQ: HGEN) for violating securities laws.

The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Humanigen disclosed on July 13, 2022 that its drug lenzilumab failed to demonstrate statistical significance on its primary endpoint in a clinical trial involving hospitalized COVID-19 patients. Based on this news, shares of Hunigen fell almost 80% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.com or by e-mail at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethical requirements.